Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors

This study is testing if a special type of PET scan that targets a protein in cancer cells can help doctors find and treat malignant tumors better.

Quick facts

• Study type: Observational
• Enrollment: 100 (estimated)
• Ages: 18 Years to 65 Years
• Sex: All
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (other)
• Drugs / interventions: CAR-T, chimeric antigen receptor, immunotherapy
• Locations: 1 site (Wuhan, Hubei)
• Trial ID: NCT06843629 on ClinicalTrials.gov

What this trial studies

Processing failed - manual review needed

Who should consider this trial

Good fit: Unknown

Not a fit: Unknown

Why it matters

Potential benefit: Unknown

How similar studies have performed: Unknown

Eligibility criteria

Inclusion Criteria:

* Each subject must meet all enrollment criteria to be eligible to participate in the study:

  1. The subject or his/her legal representative is able to sign and date the informed consent form;
  2. A commitment to comply with the research procedures and to cooperate in the implementation of the full research process;
  3. Adult patients or healthy volunteers (aged 18 or above) of either sex;
  4. Patients with clinically suspected or confirmed malignant tumors such as pancreatic cancer, ovarian cancer, or lung adenocarcinoma (supporting evidence includes serum-related tumor markers, imaging data such as ultrasound, CT, MRI, etc., and histological pathology examination, etc.) and in good general condition;
  5. Consistent with the results of specific laboratory tests;
  6. Females of childbearing potential who have been using contraception for at least one month prior to screening and who are committed to using contraception for the entire study period and until a specified time after the end of the study；
  7. Other set entry criteria.

Exclusion Criteria:

* All subjects who meet any of the exclusion criteria baseline will be excluded from the study:

  1. Those who are unable to complete a PET/MR or PET/CT examination (including inability to lie down, claustrophobia, radiophobia, etc.);
  2. Having other comorbidities;
  3. Patients with known hypersensitivity to MSLN antibody fragment developers or synthetic excipients; fasting blood glucose level greater than 11.0 mmol/L prior to 18F-FDG injection；
  4. Have a history of comorbid drug use;
  5. Patients considered by the investigator to have poor compliance;
  6. Patients during pregnancy or lactation;
  7. Persons with other factors that make participation in this test inappropriate.

Where this trial is running

Wuhan, Hubei

• Wuhan Union Hospital, China — Wuhan, Hubei, China (RECRUITING)

Study contacts

• Study coordinator: Xiaoli Lan, PhD

Conditions: Ovarian Cancer, Lung Adenocarcinoma, Pancreatic Cancer